Company Overview
About Signatur Biosciences
Signatur Biosciences is a London-based diagnostics company developing simple PCR-based tests that can detect complex diseases like breast cancer and other conditions using standard qPCR machines already present in most clinical laboratories — making sophisticated molecular diagnostics as accessible and operationally simple as a COVID-19 PCR test. Founded in 2022 and a Y Combinator S22 graduate, Signatur raised $7 million in May 2025 to scale its affordable, point-of-care compatible diagnostic solutions that address critical accessibility gaps in cancer diagnostics.
Business Model & Competitive Advantage
Signatur's smart PCR kit approach addresses a fundamental barrier in precision diagnostics: the most sensitive cancer detection tests (liquid biopsy, next-generation sequencing) require specialized expensive equipment and expert bioinformatics analysis that limits their use to major cancer centers. Signatur's tests use standard qPCR machines (which exist in regional hospitals, clinical labs, and diagnostic centers worldwide) and proprietary assay design that extracts equivalent diagnostic information from simpler equipment — democratizing access to early cancer detection beyond specialized oncology centers.
Competitive Landscape 2025–2026
In 2025, Signatur Biosciences competes in the molecular diagnostics and liquid biopsy market with Exact Sciences (Cologuard, Nasdaq: EXAS), Grail (Galleri multi-cancer early detection, Illumina), Foundation Medicine (Roche), and Guardant Health (GUARD) for cancer early detection and molecular diagnostics. The liquid biopsy and multi-cancer early detection space has attracted significant investment — Grail's Galleri test (which screens for 50+ cancers from a blood draw) represents the aspiration of the field but requires specialized sequencing infrastructure at $949 per test. Signatur's PCR-based approach could achieve widespread adoption if it delivers comparable clinical sensitivity on accessible equipment. The $7M May 2025 raise provides the runway to complete clinical validation studies. The 2025 strategy focuses on breast cancer as the lead indication, building the clinical evidence base for regulatory submission, and establishing NHS and international diagnostic laboratory partnerships.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Signatur Biosciences is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Compare Signatur Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Signatur Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Signatur Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Signatur Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →